Welcome to our dedicated page for Genenta Science Spa SEC filings (Ticker: GNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genenta Science S.p.A. (NASDAQ: GNTA) SEC filings page on Stock Titan brings together the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a foreign private issuer and clinical-stage immuno-oncology company, Genenta reports key information about its Temferon™ development programs, financing activities, and governance through Form 6-K and related filings.
In these filings, investors can find unaudited consolidated financial statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations, which outline Genenta’s cash resources, operating expenses, and funding runway in relation to its solid tumor clinical programs. Other 6-Ks describe registered direct offerings of American Depositary Shares under a shelf registration statement on Form F-3, including purchase agreements, placement agency agreements, and use-of-proceeds language.
Genenta also uses SEC filings to document a Mandatory Convertible Bond financing with ENEA Tech and Biomedical, amendments to its by-laws, changes in the size and composition of its Board of Directors, and executive leadership transitions such as the appointment or resignation of a Chief Medical Officer. Shareholder meeting notices and outcomes, including approvals of statutory financial statements and director appointments, are similarly detailed in these reports.
Through Stock Titan, users can access Genenta’s 6-Ks, registration statements, prospectus supplements, and related exhibits as they are made available on EDGAR, along with AI-powered summaries that explain the practical meaning of each document. This includes highlighting where Genenta discusses its Temferon clinical trials in glioblastoma multiforme and metastatic renal cell carcinoma, capital structure changes, and material agreements with manufacturing partners. For those monitoring insider holdings, the SEC database also provides ownership and transaction reports that complement the company’s own ownership updates.
Use this page to quickly review GNTA’s latest SEC filings, compare new disclosures with prior reports, and understand how regulatory documents reflect the evolution of Genenta’s immuno-oncology platform and corporate strategy.
Genenta Science S.p.A. has called an Ordinary and Extraordinary Shareholders’ Meeting for October 29, 2025 in virtual format, with a second-call date on October 30, 2025 if needed. Shareholders will be asked to approve amendments to Article 4 of the company’s by-laws to expand its corporate purpose to include all sectors covered by Italian Golden Power legislation.
They will also vote on increasing the Board of Directors from three to five members and on the appointment of two new board members. The notice of meeting and related materials are to be posted on Genenta’s website under the Investors section on or about September 10, 2025.